US Approves Pill Version of Popular Weight-Loss Drug Wegovy


The United States Food and Drug Administration (FDA) has approved a pill form of Wegovy, a widely used weight-loss medication originally available only by injection. This development offers a more convenient alternative for millions of Americans seeking to manage obesity and related health issues.


Wegovy, made by Danish pharmaceutical company Novo Nordisk, contains the active ingredient semaglutide, which mimics a hormone that targets areas of the brain involved in appetite regulation. The injectable form has gained massive popularity in recent years, contributing to significant weight loss in patients.


With the pill version now approved, patients who prefer not to use injections will have access to the same clinically proven benefits in oral form. Experts say this could broaden access and compliance, especially for those who are uncomfortable with needles.


The approval comes as obesity rates in the U.S. continue to rise, posing long-term health and economic challenges. Medical professionals and public health advocates have welcomed the decision, viewing it as a step toward expanding treatment options for one of the country’s most pressing health concerns.


Novo Nordisk is expected to launch the pill version of Wegovy in 2026, pending production and distribution plans. Demand is expected to be high, given the popularity of the drug in its injectable form.

Comments

Popular posts from this blog

Gambian Delegate Joins International Model OIC Conference in Istanbul, Calls for Justice for Palestine

US Pauses Offshore Wind Energy Leases Along Atlantic Coast Citing National Security Concern

U.S. President Reportedly Accuses BBC of Defamation in Florida Court Filing